WT1 peptide immunotherapy for gynecologic malignancies resistant to conventional therapies: A phase II trial

Journal of Cancer Research and Clinical Oncology

Volumn 139, Issue 3, 2013, Pages 457-463

  Miyatake, Takashi ^a   Ueda, Yutaka ^a   Morimoto, Akiko ^a   Enomoto, Takayuki ^a   Nishida, Sumiyuki ^a   Shirakata, Toshiaki ^a   Oka, Yoshihiro ^a,b   Tsuboi, Akihiro ^a   Oji, Yusuke ^a   Hosen, Naoki ^a   Nakatsuka, Shin Ichi ^c   Morita, Satoshi ^d   Sakamoto, Junichi ^e   Sugiyama, Haruo ^a   Kimura, Tadashi ^a  

^a OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b OSAKA UNIVERSITY   (Japan)

^c KANSAI ROSAI HOSPITAL   (Japan)

^d YOKOHAMA CITY UNIVERSITY MEDICAL CENTER   (Japan)

^e NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Anti tumor effect; Gynecologic malignancy; Stable disease; Survival; Toxicity; WT1 peptide immunotherapy

Indexed keywords

PEPTIDE VACCINE; UNCLASSIFIED DRUG; WT1 PEPTIDE VACCINE; CMTWNQMNL PEPTIDE; OLIGOPEPTIDE; WT1 PROTEIN;

ADULT; AGED; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER IMMUNOTHERAPY; CANCER PROGNOSIS; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; DELAYED HYPERSENSITIVITY; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; FEMALE; GYNECOLOGIC CANCER; HUMAN; JAPAN; LIVER TOXICITY; LONG TERM SURVIVAL; OUTCOME ASSESSMENT; OVARY CARCINOMA; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROSPECTIVE STUDY; SKIN TOXICITY; SURVIVAL TIME; TREATMENT DURATION; TREATMENT RESPONSE; UNIVERSITY HOSPITAL; UTERINE CERVIX CARCINOMA; UTERUS SARCOMA; CARCINOMA; DISEASE COURSE; FEMALE GENITAL TRACT TUMOR; IMMUNOTHERAPY; METHODOLOGY; MIDDLE AGED; MORTALITY; PATHOLOGY; SALVAGE THERAPY; SURVIVAL; TREATMENT FAILURE; TREATMENT OUTCOME;

ADULT; AGED; CARCINOMA; DISEASE PROGRESSION; FEMALE; GENITAL NEOPLASMS, FEMALE; HUMANS; IMMUNOTHERAPY; MIDDLE AGED; OLIGOPEPTIDES; SALVAGE THERAPY; SURVIVAL ANALYSIS; TREATMENT FAILURE; TREATMENT OUTCOME; WT1 PROTEINS;

MLCS; MLOWN;

EID: 84876307846     PISSN: 01715216     EISSN: 14321335     Source Type: Journal    
DOI: 10.1007/s00432-012-1348-2     Document Type: Article

References (17)

1. Cheever MA, Allison JP, Ferris AS, Finn OJ, Hastings BM, Hecht TT, Mellman I, Prindiville SA, Viner JL, Weiner LM, Matrisian LM (2009) The prioritization of cancer antigens: a National Cancer Institute pilot project for the acceleration of translational research. Clin Cancer Res 15:5323-5337
2. Chiyoda T, Tsuda H, Nomura H, Kataoka F, Tominaga E, Suzuki A, Susumu N, Aoki D (2010) Effects of third-line chemotherapy for women with recurrent ovarian cancer who received platinum/taxane regimens as first-line chemotherapy. Eur J Gynaecol Oncol 31:364-368
3. DiSaia PJ, Creasman WT (2002) Clinical gynecologic oncology, 6th edn. St Louis, Mosby
4. Dizon DS, Dupont J, Anderson S, Sabbatini P, Hummer A, Aghajanian C, Spriggs D (2003) Treatment of recurrent ovarian cancer: a retrospective analysis of women treated with single-agent carboplatin originally treated with carboplatin and paclitaxel. The memorial sloan-kettering cancer center experience. Gynecol Oncol 91:584-590
5. Dohi S, Ohno S, Ohno Y, Takakura M, Kyo S, Soma G, Sugiyama H, Inoue M (2011) WT1 peptide vaccine stabilized intractable ovarian cancer patient for one year: a case report. Anticancer Res 31:2441-2445
6. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, Rubinstein L, Shankar L, Dodd L, Kaplan R, Lacombe D, Verweij J (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45:228-247
7. Harries M, Gore M (2002) Part II chemotherapy for epithelial ovarian cancer-treatment of recurrent disease. Lancet Oncol 3:537-545
8. Hashii Y, Sato E, Ohta H, Oka Y, Sugiyama H, Ozono K (2010) WT1 peptide immunotherapy for cancer in children and young adults. Pediatr Blood Cancer 55:352-355
9. Izumoto S, Tsuboi A, Oka Y, Suzuki T, Hashiba T, Kagawa N, Hashimoto N, Maruno M, Elisseeva OA, Shirakata T, Kawakami M, Oji Y, Nishida S, Ohno S, Kawase I, Hatazawa J, Nakatsuka S, Aozasa K, Morita S, Sakamoto J, Sugiyama H, Yoshimine T (2008) Phase II clinical trial of Wilms tumor 1 peptide vaccination for patients with recurrent glioblastoma multiforme. J Neurosurg 108:963-971
10. Koensgen D, Stengel D, Belau A, Klare P, Oskay-Oezcelik G, Steck T, Camara O, Mustea A, Sommer H, Coumbos A, Bogenrieder T, Lichtenegger W (2008) North-Eastern german society of gynecological oncology study group-ovarian cancer. Topotecan and carboplatin in patients with platinum-sensitive recurrent ovarian cancer. Results of a multicenter NOGGO: phase I/II study. Cancer Chemother Pharmacol 62:393-400
11. Markman M, Webster K, Zanotti K, Kulp B, Peterson G, Belinson J (2003) Phase 2 trial of single-agent gemcitabine in platinum-paclitaxel refractory ovarian cancer. Gynecol Oncol 90:593-596
12. Morita S, Oka Y, Tsuboi A, Kawakami M, Maruno M, Izumoto S, Osaki T, Taguchi T, Ueda T, Myoui A, Nishida S, Shirakata T, Ohno S, Oji Y, Aozasa K, Hatazawa J, Udaka K, Yoshikawa H, Yoshimine T, Noguchi S, Kawase I, Nakatsuka S, Sugiyama H, Sakamoto J (2006) A phase I/II trial of a WT1 (Wilms' tumor gene) peptide vaccine in patients with solid malignancy: safety assessment based on the phase I data. Jpn J Clin Oncol 36:231-236
13. Nishio S, Katsumata N, Matsumoto K, Tanabe H, Kato Y, Yonemori K, Kouno T, Shimizu C, Ando M, Fujiwara Y. (2006) Analysis of third-line and forth-line chemotherapy for recurrent ovarian cancer treated with first-line platinum/taxane regimens 2006 ASCO Annual Meeting Proceedings Part I. J Clin Oncol 24 (18S June 20 Supplement):15045
14. Ohno S, Kyo S, Myojo S, Dohi S, Ishizaki J, Miyamoto K, Morita S, Sakamoto J, Enomoto T, Kimura T, Oka Y, Tsuboi A, Sugiyama H, Inoue M (2009) Wilms' tumor 1 (WT1) peptide immunotherapy for gynecological malignancy. Anticancer Res 29:4779-4784
15. Oji Y, Oka Y, Nishida S, Tsuboi A, Kawakami M, Shirakata T, Takahashi K, Murao A, Nakajima H, Narita M, Takahashi M, Morita S, Sakamoto J, Tanaka T, Kawase I, Hosen N, Sugiyama H (2010) WT1 peptide vaccine induces reduction in minimal residual disease in an imatinib-treated CML patient. Eur J Haematol 85:358-360
16. Oka Y, Sugiyama H (2010) WT1 peptide vaccine, one of the most promising cancer vaccines: its present status and the future prospects. Immunotherapy 2:591-594
17. Vergote I, Finkler N, del Campo J, Lohr A, Hunter J, Matei D, Kavanagh J, Vermorken JB, Meng L, Jones M, Brown G, ASSIST-1 Study Group (2009) Phase 3 randomised study of canfosfamide (Telcyta, TLK286) versus pegylated liposomal doxorubicin or topotecan as third-line therapy in patients with platinum-refractory or resistant ovarian cancer. Eur J Cancer 45:2324-2332